In this investigation, through rigorous in vivo preclinical evaluations, it was discerned that in B-ALL and Burkitt’s lymphoma murine models, post lymphocyte depletion via cyclophosphamide and fludarabine, administering CD19 CAR-T therapy on day five yielded optimal neoplastic cell abrogation and sustained CD19 CAR-T cell vitality, thereby optimizing murine survival trajectories. The gene discussed is CD19; the disease is Burkitt lymphoma.